Company news

Alterity Therapeutics Ltd. news in 2023

Alterity Therapeutics Ltd.'s news releases, calls and decks from 2023, newest first.

View company

Positive Efficacy Data for ATH434 in a Primate Model of PD

December 3, 2023

Alterity Therapeutics Raises $4.8M AUD in Placement

November 21, 2023

ATH completes enrolment in ATH434-201 Phase 2 clinical trial

November 7, 2023

Appendix 4E and Annual Report 2023

August 31, 2023

Alterity Presents New Data on Multiple System Atrophy

August 31, 2023

Alterity Granted New Composition of Matter Patent in Europe

August 23, 2023

Alterity receives a $4.74 million R&D Tax Refund

August 15, 2023

Ph 2 Data Monitoring Committee Recommends Continuing Trial

July 26, 2023

Investor Presentation

June 22, 2023

ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder

May 30, 2023

Appendix 4C and Quarterly Cash Flow Report

April 27, 2023

US patent grant and license agreement

March 14, 2023

First Patient Enrolled in Europe in Phase II Clinical trial

March 7, 2023

Regulatory approval for Phase II trial in France and Austria

February 16, 2023

ATH434 Clinical Trial Launched in Italy

January 24, 2023

ATH434 clinical trial launched in the US

January 9, 2023

Decks in 2023